GLB1L Products

Antibodies
GLB1L Antibody
GLB1L Antibody
NBP1-81235
Species: Hu
Applications: IHC, IHC-P
Host: Rabbit Polyclonal
GLB1L Antibody
GLB1L Antibody
H00079411-B01P
Species: Hu
Applications: WB, ELISA
Host: Mouse Polyclonal
Lysates
GLB1L Overexpression Lysate ( ...
GLB1L Overexpression Lysate (Native)
NBP2-06325
Applications: WB
GLB1L Overexpression Lysate ( ...
GLB1L Overexpression Lysate (Denat...
H00079411-T01
Species: Hu
Applications: WB
Proteins
Recombinant Human GLB1L Prote ...
Recombinant Human GLB1L Protein
H00079411-P01
Species: Hu
Applications: WB, ELISA, PA
GLB1L Recombinant Protein Ant ...
GLB1L Recombinant Protein Antigen
NBP1-81235PEP
Species: Hu
Applications: AC

Description

GLB1L, also known as Beta-galactosidase-1-like protein 3, is a member of the glycosyl hydrolase 35 family. GLB1L has a 653 amino acid long isoform that is approximately 74kDa, and two shorter isoforms that are 314 and 313 amino acids long, respectively. Current research surrounding GLB1L has shown possible interactions with diseases and disorders such as pneumonia, leber congenital amaurosis, and gangliosidosis. GLB1L has also been shown to interact with PPP1CC and ATG2A.

Bioinformatics

Entrez Human
Uniprot Human
Human
Product By Gene ID 79411
Alternate Names
  • beta-galactosidase-1-like protein
  • EC 3.2.1.23
  • EC 3.2.1
  • MGC10771
  • EC 3.2.1.-
  • galactosidase, beta 1-like

Diseases related to GLB1L

Discover more about diseases related to GLB1L.

Amaurosis
Leber Congenital Amaurosis
Corneal Diseases
Retinal Degeneration

Pathways for GLB1L

View related products by pathway and learn more about each of the pathways below.

Reverse Transcription
Aging

Research Areas for GLB1L

Find related products by research area and learn more about each of the different research areas below.

Lipid and Metabolism

Bioinformatics Tool for GLB1L

Discover related pathways, diseases and genes to GLB1L. Need help? Read the Bioinformatics Tool Guide for instructions on using this tool.
 
Vizit™, under license from BioVista Inc.